Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 [...]
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net [...]
Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne and NVIDIA, can create novel therapeutic proteins for a new era of drug development – CHICAGO—January 12, [...]
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A [...]
Veteran Technology Executive Mike Gamson Named Evozyne CEO
– Gamson to set commercial direction, strengthen foundation for growth – CHICAGO, January 9, 2023 – Evozyne, a fast-growing biology engineering company, today welcomed [...]
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors – CHICAGO—November 3, 2022 – Emalex Biosciences announced [...]
